

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

**POLL RESULTS AT THE 2025 ANNUAL GENERAL MEETING
HELD ON 9 JUNE 2026**

The board is pleased to announce that at the AGM held on 9 June 2026, the resolutions set out below were duly passed by the Shareholders by way of poll.

Reference is made to the notice of the AGM dated 24 April 2026 (the “**Original Notice**”) and the revised notice of the AGM date 13 May 2026 (the “**Revised Notice**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Notice and the Revised Notice.

POLL RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held on 9 June 2026, the following resolutions were duly passed by way of poll. Hong Kong Registrars Limited, the Company's registrar in Hong Kong, acted as the scrutineer for the purpose of vote-taking at the AGM. The poll results were as follows:

Ordinary Resolutions		Number of votes		
		For	Against	Total number of shares voted
1.	To approve the audited consolidated financial statements and the Directors' Report and the independent auditor's report of the Company for the year ended 31 December 2025.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
2.	To approve the Report of the Supervisory Committee of the Company for the year ended 31 December 2025.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
3.	To consider the reappointment of Prism Hong Kong Limited as auditors of the Company for the year ending 31 December 2026 and authorize the Directors to fix their remuneration.	298,098,000 (99.989266%)	32,000 (0.010734%)	298,130,000 (100%)
4.	To approve the remuneration proposals for Directors and supervisors of the Company for the year ending 31 December 2026.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
5.	To re-elect the directors of the ninth session of the board (" Board ") of Directors for a term of three years from 9 June 2026 until the date of annual general meeting held in 2029 and to authorise the Board to determine their remuneration:	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
	(a) To re-elect Mr. Zhang Yi as the executive Director;	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
	(b) To re-elect Mr. Xu Xiang Fu as the executive Director;	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
	(c) To re-elect Mr. Gao Qi Pin as the Independent Non-executive Director;	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
	(d) To re-elect Mr. Bai Jun Gui as the Independent Non-executive Director;	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
	(e) To re-elect Ms. Tian Jie as the Independent Non-executive Director.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)

Ordinary Resolutions		Number of votes		
		For	Against	Total number of shares voted
6.	To re-elect the supervisors of the ninth session of the supervisory committee of the Company for a term of three years from 9 June 2026 until the date of annual general meeting held in 2029 and to authorise the Board to determine their remuneration:	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
	(a) To re-elect Mr. Yan Li Yu as the Supervisor;	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
	(b) To re-elect Mr. Wang Ying Xu as the Supervisor.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
7.	To consider and approve the election and appointment of Mr. Wang Wei as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix his remuneration.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
8.	To consider and approve the election and appointment of Ms. Chi Chun Hong as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix her remuneration.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
9.	To consider and approve the election and appointment of Ms. Li Ning as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix her remuneration.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)
10.	To consider and approve the election and appointment of Ms. Yang Yang as a supervisor of the Company for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix his remuneration.	298,130,000 (100%)	0 (0%)	298,130,000 (100%)

Special Resolution		Number of votes		
		For	Against	Total number of shares voted
1.	To give a general mandate to the directors to allot, issued and deal with Domestic Shares/H Shares not exceeding 20 per cent. of the aggregate nominal value of the Domestic Shares then in issue at the date of passing this resolution; and 20 per cent. of the aggregate nominal value of the H Shares then in issue at the date of passing this resolution, respectively.	298,090,000 (99,986,583%)	40,000 (0.013417%)	298,130,000 (100%)

As at the date of the AGM, the Company's total number of issued shares were 560,250,000 Shares (comprising 387,750,000 Domestic Shares and 172,500,000 H Shares). No shareholders were required to abstain from voting at the AGM in respect of the resolutions. Therefore the total number of shares entitling the shareholders to attend and vote for or against the resolutions at the AGM was 560,250,000 shares and there were no shares entitling the shareholders to attend and vote only against the resolutions at the AGM.

As more than half and two third of the votes were casted in favour of the ordinary and special resolutions, all resolutions were duly passed.

The Board comprises four executive directors, being Mr. Zhang Hong, Mr. Zhang Xiao Guang, Mr. Zhang Yi and Mr. Xu Xiang Fu; and one independent non-executive director, Ms. Tian Jie attended the Annual General Meeting. Two executive directors, being Mr. Zhao Bao Gang and Mr. Wu Guo Wen; and two independent non-executive directors Mr. Gao Qi Pin and Mr. Bai Jun Gui did not attend due to their business commitment.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin Province, the PRC
9 June 2026

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Zhang Yi, Xu Xiang Fu and Wu Guo Wen; and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the “Latest Listed Company Announcements” page on the Stock Exchange’s website at www.hkexnews.hk for at least 7 days from the date of its posting.